Scott Gottlieb, whose last day as commissioner of the Food and Drug Administration is Friday, plans to head back to the American Enterprise Institute to work on drug pricing issues. Gottlieb announced last month that he was leaving his post to spend more time with his wife and three young daughters. As commissioner, Gottlieb showed more interest than some of his predecessors in high drug prices — which is not part of the FDA’s portfolio — and pressed for faster approvals of cheaper generic drugs in an effort to increase competition and reduce costs. “That’s a whole different paradigm.”Gottlieb said he also wants to delve into “market failures” that are keeping pharmaceutical prices high. In other drug categories, Gottlieb said, there are enough products but not robust price competition because of various rules and structures.

Source: Washington Post April 04, 2019 11:01 UTC